Related references
Note: Only part of the references are listed.Cytochrome P450: genotype to phenotype
Rosemary H. Waring
XENOBIOTICA (2020)
CYP3A4 intronic SNP rs35599367 (CYP3A4☆22) alters RNA splicing
Danxin Wang et al.
PHARMACOGENETICS AND GENOMICS (2016)
Functional Gene Variants of CYP3A4
A. N. Werk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Study of urinary 6β-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population
ES El Desoky et al.
PHARMACOLOGICAL RESEARCH (2005)
Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans
T Furuta et al.
DRUG METABOLISM AND DISPOSITION (2003)
Microsomal enzyme induction and clinical aggravation of porphyria:: The evaluation of human urinary 6β-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity
E Uejima et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects
S Saima et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method
V Özdemir et al.
PHARMACOGENETICS (2000)
Share Paper
